4-{[(Diethylamino)carbonyl]amino}-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl Diethylcarbamate | 426814-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 4-{[(Diethylamino)carbonyl]amino}-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl Diethylcarbamate
• 英文别名: [4-(diethylcarbamoylamino)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl] N,N-diethylcarbamate
• CAS: 426814-13-3
• 化学式: C₂₇H₃₁FN₈O₃
• 分子量: 534.593
• InChiKey: KVOCYZMCKYQOOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Novel carbamate-substituted pyrazolopyridine derivatives
  申请人：——

  公开号：US20040082596A1

  公开（公告）日：2004-04-29

  The invention relates to novel pyrazolopyridine derivatives of the formula (I), wherein R1 represents hydrogen or a di-C1-6-alkylaminocarbonyl group, R2 represents a rest of the formula —O—CO—NR3R4, wherein R3 and R4 are the same or different and represent a rest of the group comprising optionally substituted C 1-6 alkyl, optionally substituted C 2-6 ?alkenyl, or optionally substituted C 3-8 ? cycloalkyl: or which, together with the nitrogen atom to which they are bound, form a five- to seven-membered saturated heterocycle that may optionally contain an additional hetero atom from the group N, O, S and/or that may be optionally substituted, and to the salts, isomers and hydrates of said derivatives, as stimulants of the soluble guanylate cyclase and for use as agents for treating cardiovascular diseases, hypertonia, thromboembolic diseases and ischemia, sexual dysfunction or inflammations, and for treating diseases of the central nervous system.

  本发明涉及式(I)的新型吡唑吡啶衍生物，其中R1代表氢或二C1-6-烷基氨甲酰基基团，R2代表公式中的其余部分—O—CO—NR3R4，其中R3和R4相同或不同，代表包括可选取代的C1-6烷基、可选取代的C2-6烯基或可选取代的C3-8环烷基的基团，或者它们与它们所连接的氮原子一起形成五元至七元的饱和杂环，该杂环可以选择性地包含来自N、O、S等杂原子组成的附加杂原子，或者可以选择性地取代。本发明还涉及所述衍生物的盐、异构体和水合物，作为可溶性鸟苷酸环化酶的刺激剂，并用作治疗心血管疾病、高血压、血栓栓塞性疾病和缺血、性功能障碍或炎症以及治疗中枢神经系统疾病的药物。
• Medical uses of novel carbamate-substituted pyrazolopyridine derivatives
  申请人：Stasch Johannes-Peter

  公开号：US20050261323A1

  公开（公告）日：2005-11-24

  This invention relates to methods for treating thromboembolic disorders and ischemias, sexual dysfunction, inflammation, disorders of the central nervous system, and cardiovascular disorders other than hypertension by administering a compound of the formula wherein R 1 is H or a di-C 1-6 -alkylaminocarbonyl radical, and R 2 is a radical of the formula —O—C(X)—NR 3 R 4 wherein X is O or S. The compound may also be administered in combination with at least one organic nitrate or NO donor, or in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

  本发明涉及一种通过给予式中R1为H或二C1-6烷基氨基甲酰基基团，以及R2为式—O—C(X)—NR3R4中的基团来治疗血栓栓塞性疾病和缺血、性功能障碍、炎症、中枢神经系统疾病和除高血压以外的心血管疾病的方法。该化合物也可以与至少一种有机硝酸酯或NO供体联合给予，或与至少一种抑制环鸟苷酸单磷酸（cGMP）分解的化合物联合给予。
• NEUE CARBAMAT-SUBSTITUIERTE PYRAZOLOPYRIDINDERIVATE
  申请人：Bayer Aktiengesellschaft

  公开号：EP1339717A1

  公开（公告）日：2003-09-03
• US7105523B2
  申请人：——

  公开号：US7105523B2

  公开（公告）日：2006-09-12
• US7291622B2
  申请人：——

  公开号：US7291622B2

  公开（公告）日：2007-11-06